Gate Alpha 2nd Points Carnival Round 4 Hot Launch! Trade to Share $30,000 MORE & Alpha Points
Trade $MORE to unlock Listing Airdrops + $300K Points Prize Pool!
💰 Total Airdrop Volume: $30,000 MORE, Limited slots—first come, first served!
✅ Total Points: 2 Alpha Points per trade—accumulate points to share the $300K prize pool!
🔥Trade the Hottest On-Chain Assets First
For more information: https://www.gate.com/campaigns/1342alpha?pid=X&c=MemeBox&ch=vxDB0fQ5
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a "buy" rating.